China’s next drug-price reset runs on provincial clocks
Fujian’s new notice and Beijing’s rollout show separate price, procurement and payment switches. The 70% payment-standard rule also needs a floor—not a reimbursement shortcut.
Regulation
NMPA, FDA, and other regulatory reads.
China targets hospital formulary barriers for eligible innovative drugs
A four-agency notice addresses formulary limits, hospital performance metrics and payment exceptions for eligible innovative drugs. Uptake remains to be demonstrated.
China cleared Lilly’s weight-loss pill a week after CIIE. The BMI line stayed American.
Orforglipron is China’s first oral GLP-1 for weight loss. The NMPA label still starts at BMI 27/30, while Novo’s injection was rewritten last month to China’s 24/28 scale.
Reading China’s TGCT market through Beijiemai: hospitals first, reimbursement still open
China approved Beijiemai first, Merck sells it, hospitals wrote the first Rxs—while list price and NRDL remain the open China-market questions behind today’s FDA headline.
Abbisko’s pimicotinib at FDA: reading the China-to-Merck path
FDA approval is the headline; the BD story is the staged Merck license—$70m upfront, $85m global option, up to $605.5m total, plus a $20m U.S. first-sale milestone.
Abbisko’s pimicotinib wins FDA approval for TGCT
China-origin CSF-1R inhibitor cleared in the U.S. after NMPA, Canada, and Switzerland—Merck KGaA holds global rights.